Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.
GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most ...
The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback